ImmunoPrecise Antibodies Ltd. (IPA)
Automate Your Wheel Strategy on IPA
With Tiblio's Option Bot, you can configure your own wheel strategy including IPA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IPA
- Rev/Share 0.7305
- Book/Share 0.7648
- PB 1.0105
- Debt/Equity 0.5146
- CurrentRatio 2.322
- ROIC -0.313
- MktCap 35369123.8745
- FreeCF/Share -0.2852
- PFCF -3.7749
- PE -0.5505
- Debt/Assets 0.2839
- DivYield 0
- ROE -1.4808
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor relations and communications initiatives. CORE IR specializes in working with emerging and established growth companies to enhance investor awareness, strengthen shareholder engagement, and broaden outreach to various institutional and retail audie.
Read More
IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)---- $AMD #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai™ platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and cos.
Read More
ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Neutral
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q3 2025 Earnings Conference Call March 28, 2025 10:30 AM ET Company Participants Jennifer Bath - Chief Executive Officer and President Joseph Scheffler - Interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
Read More
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share. The Company's common stock will t.
Read More
About ImmunoPrecise Antibodies Ltd. (IPA)
- IPO Date 2002-01-07
- Website https://www.ipatherapeutics.com
- Industry Biotechnology
- CEO Dr. Jennifer Lynne Bath Ph.D.
- Employees 72